<DOC>
	<DOCNO>NCT01872572</DOCNO>
	<brief_summary>This Phase 1a , single-center , double-blind , randomize , placebo-controlled study safety , tolerability , PK , PD single ascending dos RB006 administer SC injection , without IV RB007 ( active control agent RB006 ) , healthy young volunteer . The study originally plan enroll 4 cohort 8 subject ( N=32 ) ; however , upon review cohort ( Cohort 1-A ) necessary order fully define PK profile SC RB006 . Therefore , 36 subject enrol study . Each cohort balance sex 2/3 one sex enrol particular cohort ( i.e. , 5 8 subject cohort ) . No subject participate &gt; 1 dose group , progression next high dose occur prior dose level well tolerate , assess Safety Review Committee ( SRC )</brief_summary>
	<brief_title>Safety , Tolerability PK/PD RB006 Healthy Volunteer SAD</brief_title>
	<detailed_description />
	<criteria>1 . An Institutional Review Board ( IRB ) approve informed consent sign date prior studyrelated activity . 2 . Subject age 18 45 year , inclusive . 3 . Subject female negative urine serum pregnancy test postmenopausal least 1 year prior randomization . 4 . Subject body mass index ( BMI ) 18 kg/m2 32 kg/m2 ( weight/ [ height ] 2 ) ≥50 kg ≤120 kg total body weight . 5 . Subject normal ( abnormal clinically insignificant ) laboratory value Screening . 6 . Subject medically normal significant abnormal finding Screening physical examination . 7 . Subject ability understand requirement study willingness comply study procedure . 8 . Subject consume agreed abstain take dietary supplement nonprescription drug 9 . Subject consume agreed abstain take prescription drug 10 . Subject consume alcoholcontaining beverage 3 day prior CRU admission 11 . Subject consume grapefruit grapefruit juice within 14 day prior CRU admission 12 . Subject use tobacco nicotinecontaining product within 6 month prior CRU admission 1 . Evidence history clinically significant oncologic , pulmonary , hepatic , gastrointestinal ( GI ) , cardiovascular , hematologic , metabolic , neurological , immunologic , nephrologic , endocrine , psychiatric disease . 2 . Any evidence history intracranial bleeding , aneurysm , thrombotic hemorrhagic stroke . 3 . Any known individual family history bleed diathesis coagulopathy . 4 . Active expect menstruation Treatment Phase ( female ) . 5 . History thrombocytopenia associate abnormal bleeding risk bleed event , screen baseline platelet count &lt; 100,000/mm3 . 6 . History thrombocytosis associate thrombotic event risk thrombotic event , screen baseline platelet count &gt; 600,000/mm3 . 7 . Endoscopically confirm peptic ulcer disease within 3 year CRU admission GI bleeding within 3 month CRU admission , include positive stool occult blood Screening Baseline . 8 . Urinary tract bleed within 3 month CRU admission , include microscopic hematuria screen baseline urinalysis . 9 . Unusual prolonged bleeding ( e.g. , gum bleeding , nosebleed , easy bruising ) , document SelfReported Bleeding Questionnaire , Screening . 10 . Severe trauma , fracture , major surgery , biopsy parenchymal organ within 3 month CRU admission . 11 . Severe persistent hypertension ( systolic pressure &gt; 180 mmHg diastolic pressure &gt; 110 mmHg ) . 12 . Baseline hemoglobin &lt; 12.0 g/dL male &lt; 11.0 g/dL female ; prothrombin time ( PT ) great ULN ; aPTT great ULN . 13 . Clinically significant liver dysfunction ( e.g. , evidence elevate liver function test ) . 14 . Clinically significant renal dysfunction ( e.g. , estimate glomerular filtration rate &lt; 60 mL/min serum creatinine &gt; 1.5 mg/dL ) . 15 . History illicit drug abuse past year current evidence abuse opinion Investigator . 16 . Positive finding urine drug screen . 17 . Positive finding human immunodeficiency virus , hepatitis B , and/or hepatitis C Screening . 18 . Pregnant lactating . 19 . Acute illness within 1 week CRU admission . 20 . A history alcohol abuse past year relative CRU admission . 21 . Donated plasma within 7 day study drug administration . 22 . Donated 1 pint blood ( equivalent blood loss ) within 6 week prior study drug administration . 23 . Use investigational drug within 30 day prior CRU admission prior REG1 Anticoagulation System exposure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>